Radiopharm Theranostics RADX
NASDAQ RADX
$1.44 -0.18 (-11.11%)
As of: Oct 1, 2026 · 10:36 AM EDT

Radiopharm Theranostics (RADX) Common Equity (2023 - 2026)

Updated

Radiopharm Theranostics (RADX) posted Common Equity of $158,354 for fiscal Q4 2026 (quarter ended Jun 30, 2026), down 42.3% from $274,566 a year earlier.

Analysis

Radiopharm Theranostics (RADX) Common Equity (2023 - 2026) Analysis & Trends

At the end of FY2026 (ended Jun 30, 2026), Radiopharm Theranostics' Common Equity came in at $151,613, down 99.6% from FY2025.

  • Annual Common Equity shows a three-year compound annual growth rate of -85.1% (FY2023 to FY2026).
  • In prior fiscal years, Radiopharm Theranostics' Common Equity was $42.87 million in FY2025 (+56.7%), $27.35 million in FY2024 (-40.0%) and $45.58 million in FY2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Common Equity (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn 84.97 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn -5.94 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn 41.98 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn 41.95 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn 50.37 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn 11.69 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn 11.83 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn 85.49 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn 20.25 Bn
10 Radiopharm Theranostics 5.74 Bn 5.70 Bn 186,835.86 158,353.79
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 158,353.79
Jun 30, 2025 274,565.91
Dec 31, 2024 52.00 Mn
Jun 30, 2024 180,264.85
Jun 30, 2023 45.58 Mn
API Access

Radiopharm Theranostics Common Equity API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=common-equity&ticker=RADX&period=max&api_key=YOUR_API_KEY